Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1769-1774

  Ramanathan, Ramesh K ^a,c   Egorin, Merrill J ^a   Eiseman, Julie L ^a   Ramalingam, Suresh ^a   Friedland, David ^a   Agarwala, Sanjiv S ^a   Ivy, S Percy ^b   Potter, Douglas M ^a   Chatta, Gurkamal ^a   Zuhowski, Eleanor G ^a   Stoller, Ronald G ^a   Naret, Cynthia ^a   Guo, Jianxia ^a   Belani, Chandra P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; HEAT SHOCK PROTEIN 90; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 70; MACROCYCLIC LACTAM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HUMAN; MALE; MYALGIA; NAUSEA; PANCREATITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; BLOOD; BLOOD CELL; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BLOOD CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TREATMENT FAILURE;

EID: 34250160933     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2233     Document Type: Article

References (22)

1. Sausville EA. Biology of heat shock proteins: opportunities for cancer management. Am Soc Clin Oncol Ed Book 2006;131-5.
2. Solit DB. Heat Shock protein 90 as a therapeutic target in solid tumors. Am Soc Clin Oncol Ed Book 2006;136-40.
3. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
4. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
5. Konstantinopoulos PA, Papavassiliou AG. 17-AAG: mechanisms of antitumour activity. Expert Opin Investig Drugs 2005;14:1471-4.
6. Banerji U, O'Donnell A, Scurr M, et al. I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
7. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
8. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
9. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
10. Solit DB, Anana M, Valentin G, et al. Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 2003;22:198.
11. Kosan Biopharmaceuticals. Investigator's brochure for KOS-953. December 2005.
12. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-96.
13. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
14. Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806-12.
15. Chen X, Bies RR, Ramanathan RK, Zuhowski EG, Trump DL, Egorin MJ. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. Cancer Chemother Pharmacol 2005;55:237-43.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
17. Erlichman C, Toft D, Reid J, et al. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93.
18. Zhang H, Chung D, Yang Y, et al. Identification of newb iomarkers for clinical trials of hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64.
19. Eiseman JL, Guo J, Weinbaum B, et al. Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2005;23:155.
20. Wessinger NL, Kane SE. 17AAG combinations with conventional chemotherapeutic agents in two ovarian cancer cell lines. Proc Am Assoc Cancer Res 2002;43:950-1.
21. Nguyen DM, Lorang D, Chen GA, Stewart JH, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371- 8.
22. Solit DB, Egorin MJ, Valentin G, et al. Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeldanamycin). Proc Am Soc Clin Oncol 2004;22:203.